Lau B H, Wang-Cheng R M, Tosk J
J Leukoc Biol. 1987 May;41(5):407-11. doi: 10.1002/jlb.41.5.407.
Three routes of immunotherapy with Corynebacterium parvum (CP) on an ascitic Friend virus-induced leukemia were evaluated. Only the intraperitoneal route, which provided optimal contact between CP and tumor cells, showed prolonged mean survival time. Greatest effectiveness was obtained with multiple injections of CP at weekly intervals and with small initial tumor load. Of particular interest was that lower dosages of CP (5 and 25 micrograms) gave longer protection than dosages of 50 and 250 micrograms. Using in vitro 125I-iododeoxyuridine release assay, these lower dosages were shown to selectively enhance the cytotoxicity associated with T lymphocytes, whereas higher dosages appeared to primarily augment the activity of phagocytes. Moderate natural killer cell activity was observed with both the lower and higher dosages of CP. Data from this study indicate that route of administration, dosage of CP, and size of tumor burden are crucial variables determining optimal response to immunotherapy.
评估了用微小棒状杆菌(CP)对腹水型弗氏病毒诱发白血病进行免疫治疗的三种途径。只有腹腔内途径,能使CP与肿瘤细胞实现最佳接触,该途径显示出平均存活时间延长。每周间隔多次注射CP且初始肿瘤负荷较小时,能获得最大疗效。特别值得关注的是,较低剂量的CP(5微克和25微克)比50微克和250微克的剂量提供了更长时间的保护。通过体外125I - 碘脱氧尿苷释放试验表明,这些较低剂量可选择性增强与T淋巴细胞相关的细胞毒性,而较高剂量似乎主要增强吞噬细胞的活性。较低和较高剂量的CP均观察到适度的自然杀伤细胞活性。本研究数据表明,给药途径、CP剂量和肿瘤负荷大小是决定免疫治疗最佳反应的关键变量。